| Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond |
50 |
| Molecular interactions at the surface of extracellular vesicles |
40 |
| Hemostasis, endothelial stress, inflammation, and the metabolic syndrome |
34 |
| Neurogenic inflammation and its role in migraine |
32 |
| The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility |
28 |
| Monocyte and macrophage immunometabolism in atherosclerosis |
27 |
| Complement in the pathogenesis of Alzheimer's disease |
27 |
| Sex differences in vaccine-induced humoral immunity |
25 |
| Skin neurogenic inflammation |
24 |
| Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells |
23 |
| The pathogenicity of Th17 cells in autoimmune diseases |
23 |
| Islet inflammation in type 2 diabetes |
23 |
| The first line of defence: insights into mechanisms and relevance of phagocytosis in epithelial cells |
21 |
| Extracellular vesicles and their immunomodulatory functions in pregnancy |
17 |
| Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation |
17 |
| Principles of adoptive T cell therapy in cancer |
17 |
| The eye as a complement dysregulation hotspot |
17 |
| T cell pathology in skin inflammation |
17 |
| Neurogenic inflammation in fibromyalgia |
16 |
| Efferocytosis in the tumor microenvironment |
16 |
| Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer |
15 |
| Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? |
15 |
| The role of inflammation in diabetic eye disease |
15 |
| CD8(+) T cell exhaustion |
14 |
| Complement as a regulator of adaptive immunity |
14 |
| Tumor-derived exosomes, microRNAs, and cancer immune suppression |
14 |
| Sex differences in autoimmune disorders of the central nervous system |
14 |
| Extracellular vesicle-mediated MHC cross-dressing in immune homeostasis, transplantation, infectious diseases, and cancer |
13 |
| Treg cells in autoimmunity: from identification to Treg-based therapies |
13 |
| Does patient age influence anti-cancer immunity? |
12 |
| Diseases of complement dysregulation-an overview |
12 |
| The role of extracellular vesicles when innate meets adaptive |
12 |
| Macrophage-microbe interaction: lessons learned from the pathogen Mycobacterium tuberculosis |
12 |
| Sex differences in tuberculosis |
11 |
| Orchestration of intestinal homeostasis and tolerance by group 3 innate lymphoid cells |
11 |
| Complement activation, a threat to pregnancy |
11 |
| Structural and functional diversity of collectins and ficolins and their relationship to disease |
11 |
| Expanding horizons in complement drug discovery: challenges and emerging strategies |
11 |
| Sex and sex steroids impact influenza pathogenesis across the life course |
10 |
| Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome? |
9 |
| Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1? |
9 |
| The role of interleukin-6 in glucose homeostasis and lipid metabolism |
9 |
| Therapeutic cancer vaccine: building the future from lessons of the past |
8 |
| Intricate relationships between naked viruses and extracellular vesicles in the crosstalk between pathogen and host |
8 |
| Innate lymphoid cells in autoimmunity and chronic inflammatory diseases |
7 |
| Memory responses of innate lymphocytes and parallels with T cells |
7 |
| Molecular determinants for the polarization of macrophage and osteoclast |
7 |
| Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients |
7 |
| Resolution of neuroinflammation: mechanisms and potential therapeutic option |
6 |
| Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes |
6 |
